

**Analyst**

John Hester 612 8224 2871

**Authorisation**

Alex McLean 612 8224 2886

# COVID19 Snapshot

## We're not out of the woods just yet

Daily Summary					
New Cases of COVID19	13-May-20	12-May-20	11-May-20	10-May-20	9-May-20
Global	83,761	85,147	66,841	79,825	86,966
# countries >500 new	12	13	10	11	14
Most new infections	USA	USA	USA	USA	USA
#	19,103	22,802	14,589	20,329	23,871
Countries recording fewer new cases than the previous day	13	10	15	15	20
<b>Active Cases (total infections less deaths and clearances)</b>					
Global	2,469,360	2,447,121	2,436,392	2,403,919	2,385,407
Countries with fewer active cases than the previous day	13	16	9	12	11
<b>Top 5 Countries with active case load</b>					
USA	1,034,862	1,028,465	1,040,336	1,030,515	1,029,503
United Kingdom	196,175	193,427	190,651	186,984	183,329
Russia	192,056	186,615	179,534	173,467	164,933
France	92,313	93,284	94,056	94,373	94,310
Brazil	97,401	92,601	89,862	86,619	86,015
<b>Fewest Active Cases</b>					
Austria	1,069	1,190	1,201	1,262	1,290
South Korea	1,008	1,008	1,021	1,008	1,016
<b>Australia Active Cases</b>					
New Infections	16	16	7	12	15
Active cases	611	638	672	681	697

SOURCE: WORLDOMETER

NSW has had a good few days with no new recorded cases on Tuesday and only 6 yesterday. China – Wuhan province has reported 5 outbreaks of the infection since the lockdown was lifted in early April. The outbreaks are being traced to ‘clusters’ in residential compounds and hospitals, however, there are no reports at this time of a general lock down being re-introduced.

U.S. biotech firm Moderna Therapeutics (MRNA), has been granted FDA fast track status in addition to up to US\$483m in grant funding from BARDA to accelerate development of its vaccine candidate mRNA-1273 against the novel corona virus. The company is now in preparation for a 600 patient phase 2 study. Participants in the study will be followed for 12 months following vaccination. Unfortunately the time lines can't be shortened. Moderna is one of many companies in the race to develop a vaccine including numerous biotech companies from the US as well as university led research.

As Australia begins to ease COVID19 restrictions, the economic cost of the virus is manifesting in measure beyond unemployment. In this week's quarterly CBA's key assumptions include a 7% GDP contraction, 9% unemployment and a 32% fall in Australian housing prices in a prolonged economic downturn. As a result the bank made an additional \$1.5bn balance sheet provision for asset write downs, the vast majority of which is directly attributable to COVID19 losses. CBA has received 144,000 requests for home loan repayment deferrals.

T

**Recommendation structure**

**Buy:** Expect >15% total return on a 12 month view. For stocks regarded as 'Speculative' a return of >30% is expected.

**Hold:** Expect total return between -5% and 15% on a 12 month view

**Sell:** Expect <-5% total return on a 12 month view

*Speculative Investments are either start-up enterprises with nil or only prospective operations or recently commenced operations with only forecast cash flows, or companies that have commenced operations or have been in operation for some time but have only forecast cash flows and/or a stressed balance sheet.*

*Such investments may carry an exceptionally high level of capital risk and volatility of returns.*

**Research Team**

Staff Member	Title/Sector	Phone	@bellpotter.com.au
TS Lim	Head of Research	612 8224 2810	tslim
<b>Industrials</b>			
James Filius	Industrials	613 9235 1612	jfilius
Sam Haddad	Industrials	612 8224 2819	shaddad
Alex McLean	Industrials	612 8224 2886	amclean
Hamish Murray	Industrials	613 9235 1813	hmurray
Chris Savage	Industrials	612 8224 2835	csavage
Jonathan Snape	Industrials	613 9235 1601	jsnape
Damien Williamson	Industrials	613 9235 1958	dwilliamson
<b>Healthcare/Biotech</b>			
John Hester	Healthcare	612 8224 2871	jhester
Tanushree Jain	Healthcare/Biotech	612 8224 2849	tnjain
<b>Financials</b>			
TS Lim	Banks/Regionals	612 8224 2810	tslim
Lafitani Sotiriou	Diversified Financials/Fintech	613 9235 1668	Isotiriou
<b>Resources</b>			
Peter Arden	Resources	613 9235 1833	parden
David Coates	Resources	612 8224 2887	dcoates
Stuart Howe	Resources	613 9235 1856	showe
<b>Associates</b>			
Joseph House	Associate Analyst	613 9235 1624	jhouse

**Bell Potter Securities Limited**  
ACN 25 006 390 7721  
Level 29, 101 Collins Street  
Melbourne, Victoria, 3000  
Telephone +61 3 9256 8700  
[www.bellpotter.com.au](http://www.bellpotter.com.au)

**Bell Potter Securities (HK) Limited**  
Room 1701, 17/F  
Prosperity Tower, 39 Queens Road  
Central, Hong Kong, 0000  
Telephone +852 3750 8400

**Bell Potter Securities (US) LLC**  
Floor 39  
444 Madison Avenue, New York  
NY 10022, U.S.A  
Telephone +1 917 819 1410

**Bell Potter Securities (UK) Limited**  
16 Berkeley Street  
London, England  
W1J 8DZ, United Kingdom  
Telephone +44 7734 2929

**The following may affect your legal rights. Important Disclaimer:**

This document is a private communication to clients and is not intended for public circulation or for the use of any third party, without the prior approval of Bell Potter Securities Limited. In the USA and the UK this research is only for institutional investors. It is not for release, publication or distribution in whole or in part to any persons in the two specified countries. **In Hong Kong**, this research is being distributed by Bell Potter Securities (HK) Limited which is licensed and regulated by the Securities and Futures Commission, Hong Kong. **In the United States**, this research is issued and distributed by Bell Potter Securities (US) LLC which is a registered broker-dealer and member of FINRA. Any person receiving this report from Bell Potter Securities (US) LLC and wishing to transact in any security described herein should do so with Bell Potter Securities (US) LLC.

This is general investment advice only and does not constitute personal advice to any person. Because this document has been prepared without consideration of any specific client's financial situation, particular needs and investment objectives ('relevant personal circumstances'), a Bell Potter Securities Limited investment adviser (or the financial services licensee, or the representative of such licensee, who has provided you with this report by arrangement with Bell Potter Securities Limited) should be made aware of your relevant personal circumstances and consulted before any investment decision is made on the basis of this document.

While this document is based on information from sources which are considered reliable, Bell Potter Securities Limited has not verified independently the information contained in the document and Bell Potter Securities Limited and its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. Nor does Bell Potter Securities Limited accept any responsibility for updating any advice, views opinions, or recommendations contained in this document or for correcting any error or omission which may become apparent after the document has been issued.

Except insofar as liability under any statute cannot be excluded. Bell Potter Securities Limited and its directors, employees and consultants do not accept any liability (whether arising in contract, in tort or negligence or otherwise) for any error or omission in this document or for any resulting loss or damage (whether direct, indirect, consequential or otherwise) suffered by the recipient of this document or any other person.

**Research Policies:**

For Bell Potter's Research Coverage Decision Making Process and Research Independence Policy, please refer to our company website:

<https://www.bellpotter.com.au/topnavigation/private-clients/stockbroking/research>

**Disclosure of interest:**

Bell Potter Securities Limited, its employees, consultants and its associates within the meaning of Chapter 7 of the Corporations Law may receive commissions, underwriting and management fees from transactions involving securities referred to in this document (which its representatives may directly share) and may from time to time hold interests in the securities referred to in this document.

**ANALYST CERTIFICATION**

Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.